Results 121 to 130 of about 40,773 (330)
New prospects for PCSK9 inhibition? [PDF]
Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2018.
U. Landmesser+22 more
openaire +5 more sources
This study reveals a novel crosstalk between hepatic SREBP2‐mediated cholesterol biosynthesis pathway and peripheral lipoprotein lipase‐mediated lipolysis pathway in the regulation of systemic lipid metabolism. Notably, the lipid‐lowering effects of SREBP2 inhibition are independent of a functional LDL receptor, highlighting the potential of acute ...
Yifan Wang+13 more
wiley +1 more source
Statins have been approved for the treatment of dyslipidemia for 25 years. This class has demonstrated substantial and consistent reduction of cardiovascular events with an acceptable safety profile. Despite the widespread use of statins, patients continue to experience residual risk. To date,
openaire +3 more sources
xxxx. Abstract Nutrient metabolisms are vitally interrelated to cancer progression and immunotherapy. However, the mechanisms by which nutrient metabolisms interact to remodel immune surveillance within the tumor microenvironment remain largely unexplored.
Qi‐Long Wang+16 more
wiley +1 more source
Internalized PCSK9 dissociates from recycling LDL receptors in PCSK9-resistant SV-589 fibroblasts
Secreted PCSK9 binds to cell surface LDL receptor (LDLR) and directs the receptor for lysosomal degradation. PCSK9 is potent at inducing LDLR degradation in cultured liver-derived cells, but it is considerably less active in immortalized fibroblasts.
My-Anh Nguyen+2 more
doaj
Studies on PCSK9 in the regulation of cholesterol metabolism [PDF]
Elevated levels of plasma cholesterol, mainly in low density lipoproteins (LDL), are a major risk factor for coronary heart disease. The level of plasma LDL cholesterol (LDL-C) is largely dependent on the number of hepatic LDL receptors (LDLRs ...
Persson, Lena
core +1 more source
The last decades of research in cardiovascular prevention have been characterized by successful bench-to-bedside developments for the treatment of low-density lipoprotein (LDL) hypercholesterolemia.
J. Katzmann, A. Cupido, U. Laufs
semanticscholar +1 more source
PCSK9 monoclonal antibodies: An overview
PCSK9 monoclonal antibodies are novel lipid-lowering therapy that have been extensively studied in patients with hypercholesterolemia either as monotherapy or as an add-on to other LLTs. PCSK9 monoclonal antibodies have significantly reduced the low-density lipoprotein cholesterol (LDL-C) plasma level resulting in a better LDL-C goal attainment.
Bassant Orabi+2 more
openaire +4 more sources
The contribution of extracellular RNA and its derived biomaterials in disease management
The implications of exRNA's biological function and the structural uniqueness of RNA help establish a close connection between RNA, material, and modern medicine. Abstract The RNA found in the circular system is known as extracellular RNA (exRNA). This kind of RNA has been found to play a biological role similar to that of a messenger. They can be used
Yu Wei+8 more
wiley +1 more source
Background Proprotein convertase subtilisin/kexin type 9 (PCSK9) is of particular importance in cholesterol metabolism with high levels contributing to hypercholesterolemia. Cholesterol and sphingolipids are low in patients with liver cirrhosis.
Susanne Feder+7 more
doaj +1 more source